Table 3.
Log-rank analysis of factors for PFS.
| Variable | No. of cases | PFS (median, 95% CI) | P-value | |
|---|---|---|---|---|
| Total patients | 36 | 3.82 | (3.664–3.979) | |
| Median Age range | ||||
| <60 | 25 | 3.86 | (0.078–7.636) | 0.069 |
| ≥60 | 11 | 3.36 | (2.327–4.387) | |
| Gender | ||||
| Male | 17 | 5.14 | (0.657–9.629) | 0.358 |
| Female | 19 | 3.82 | (3.470–4.173) | |
| ECOG performance status | ||||
| 0–1 | 25 | 6.2 | (2.441–9.917) | 0.078 |
| ≥2 | 11 | 3.57 | (3.318–3.825) | |
| Location | ||||
| Left | 28 | 3.82 | (2.012–5.631) | 0.619 |
| Right | 8 | 3.86 | (3.430–4.284) | |
| KRAS status | ||||
| unknown | 7 | 3.86 | (2.267–5.448) | 0.627 |
| wild | 17 | 3.71 | (3.330–4.098) | |
| mutant | 12 | 3.82 | (3.664–3.979) | |
| Line of apatinib | ||||
| 3 line | 21 | 3.82 | (3.668–3.975) | 0.52 |
| Further line | 15 | 5.14 | (2.578–7.707) | |
| Apatinib combined | ||||
| Yes | 22 | 5.14 | (1.878–8.408) | 0.414 |
| No | 14 | 3.71 | (3.190–4.238) | |
| Bevacizumab prior to apatinib | ||||
| Yes | 23 | 3.79 | (1.491–6.224) | 0.538 |
| No | 13 | 3.86 | (3.387–4.185) | |
| Hypertension | ||||
| Yes | 10 | 6.90 | (0.000–15.577) | 0.055 |
| No | 26 | 3.54 | (3.100–3.900) | |
| Hand-food syndrome(HFS) | ||||
| Yes | 12 | 3.83 | (1.876–5.724) | 0.347 |
| No | 24 | 3.82 | (3.476–4.124) | |
| Nausea and Vomiting | ||||
| Yes | 12 | 3.80 | (3.263–9.337) | 0.674 |
| No | 24 | 6.30 | (3.339–4.251) | |
Univariate analysis indicated that there was no significant association of PFS with age,gender, ECOG PS, location, KRAS status, line of therapy, Apatinib combined or not and Bevacizumab prior to apatinib. p values by log-rank test are displayed.